Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Raises Target Price to $400
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Morgan Stanley has maintained its hold rating for Alnylam Pharmaceuticals, while increasing its target price. The new target price is $400. This change reflects a revision in the firm's outlook for the company.